Combination of a solid cost-control strategy, improving new student enrollments, brand building and growth investments and an upbeat outlook are the rank drivers for this stock.
Continued progress on its performance improvement plan to align costs, regain enrollment growth and make growth investments helped the company to turnaround from the past few weak quarterly results.
Synergy Pharma will be enrolling 350 patients suffering from IBS-C around 70 sites in the US. These patients will be treated with any one of the four doses of plecanatide (0.3, 1.0, 3.0, or 9.0 mg) or placebo for 12 weeks.
The trial will be evaluating the average change in complete spontaneous bowel movements (CSBM’s) during the trial period in comparison to their baseline weekly CSBM rate that was established during the screening phase of the study. In addition to this, Synergy Pharma will be evaluating spontaneous bowel movements (SBM’s) and daily abdominal pain, discomfort along with bloating scores and impact of the candidate on disease-specific quality of life measures during the study.
We note that Synergy Pharma is conducting an independent study on plecanatide for the treatment of patients suffering from chronic idiopathic constipation. The company expects to complete the study soon and report top-line results within a few weeks.
Synergy Pharma currently carries a Zacks #3 Rank (Hold) in the short run. Meanwhile, Ironwood Pharma carries a Zacks #2 Rank (Buy).
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
SOURCE Zacks Investment Research, Inc.